A detailed history of Alyeska Investment Group, L.P. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 203,184 shares of JANX stock, worth $11.4 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
203,184
Previous 199,384 1.91%
Holding current value
$11.4 Million
Previous $8.35 Million 10.51%
% of portfolio
0.05%
Previous 0.05%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$35.29 - $50.26 $134,102 - $190,988
3,800 Added 1.91%
203,184 $9.23 Million
Q2 2024

Aug 14, 2024

BUY
$35.12 - $64.78 $222,590 - $410,575
6,338 Added 3.28%
199,384 $8.35 Million
Q1 2024

May 15, 2024

SELL
$7.93 - $49.75 $35,240 - $221,089
-4,444 Reduced 2.25%
193,046 $7.27 Million
Q4 2023

Feb 14, 2024

BUY
$5.85 - $11.7 $1.16 Million - $2.31 Million
197,490 New
197,490 $2.12 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.34B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.